Found: 11
Select item for more details and to access through your institution.
Assessing the treatment pattern, health care resource utilisation, and economic burden of multiple myeloma in France using the Système National des Données de Santé (SNDS) database: a retrospective cohort study.
- Published in:
- European Journal of Health Economics, 2023, v. 24, n. 3, p. 321, doi. 10.1007/s10198-022-01463-9
- By:
- Publication type:
- Article
Effectiveness and safety of belantamab mafodotin in patients with relapsed or refractory multiple myeloma in real‐world setting: The ALFA study.
- Published in:
- European Journal of Haematology, 2024, v. 113, n. 3, p. 310, doi. 10.1111/ejh.14222
- By:
- Publication type:
- Article
Survival outcomes for patients with multiple myeloma in France: A retrospective cohort study using the Système National des Données de Santé national healthcare database.
- Published in:
- European Journal of Haematology, 2023, v. 111, n. 1, p. 125, doi. 10.1111/ejh.13976
- By:
- Publication type:
- Article
Treatment preferences of patients with relapsed or refractory multiple myeloma in the United States, United Kingdom, Italy, Germany, France, and Spain: results from a discrete choice experiment.
- Published in:
- Frontiers in Medicine, 2023, p. 1, doi. 10.3389/fmed.2023.1271657
- By:
- Publication type:
- Article
P-202: Characterization of ocular adverse events in patients receiving Belantamab Mafadotin for ≥12 months: post-hoc analysis of DREAMM-2 study in relapsed/refractory Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S149, doi. 10.1016/S2152-2650(21)02329-6
- By:
- Publication type:
- Article
MM-200: A Qualitative Study of Patients' Preferences for the Treatment of Relapsed or Refractory Multiple Myeloma (RRMM) in the United States, United Kingdom, France, and Germany.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S428, doi. 10.1016/S2152-2650(21)01955-8
- By:
- Publication type:
- Article
MM-123: Real-World Study of Treatment Patterns in Heavily Pretreated Relapsed/Refractory Multiple Myeloma (RRMM) in the US.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S423, doi. 10.1016/S2152-2650(21)01947-9
- By:
- Publication type:
- Article
MM-078: Characterization of Ocular Adverse Events in Patients Receiving Belantamab Mafodotin (Belamaf) for ≥12 Months: Post Hoc Analysis of DREAMM-2 Study in Relapsed/Refractory Multiple Myeloma (RRMM).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S419, doi. 10.1016/S2152-2650(21)01940-6
- By:
- Publication type:
- Article
Poster: MM-200: A Qualitative Study of Patients' Preferences for the Treatment of Relapsed or Refractory Multiple Myeloma (RRMM) in the United States, United Kingdom, France, and Germany.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S255, doi. 10.1016/S2152-2650(21)01598-6
- By:
- Publication type:
- Article
Poster: MM-123: Real-World Study of Treatment Patterns in Heavily Pretreated Relapsed/Refractory Multiple Myeloma (RRMM) in the US.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S253, doi. 10.1016/S2152-2650(21)01589-5
- By:
- Publication type:
- Article
Poster: MM-078: Characterization of Ocular Adverse Events in Patients Receiving Belantamab Mafodotin (Belamaf) for ≥ 12 Months: Post Hoc Analysis of DREAMM-2 Study in Relapsed/Refractory Multiple Myeloma (RRMM).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S251, doi. 10.1016/S2152-2650(21)01576-7
- By:
- Publication type:
- Article